What makes a drug a blockbuster — or a cautionary tale?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hey there. Today, we talk about how biomanufacturing is getting a huge boost in North Carolina, study a new potential root for autoimmune disease in women, and more.

The need-to-know this morning

• Bristol Myers Squibb reported fourth quarter and 2023 earnings. For 2024, the company said it expects total sales to increase “low single digits” from $45 billion in 2023. Current Street consensus has Bristol growing sales 2%.
• More earnings: Regeneron Pharmaceuticals and Abbvie.

What makes a blockbuster?

Can biotech learn from Aduhelm? And how do you replace a singular regulator? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In